INTRODUCTION

51
The emergence of multidrug-resistant tuberculosis (MDR-TB; 580,000 cases worldwide), 52 which is resistant to at least rifampin (RIF) and isoniazid (INH) , and, more recently, 53 extensively drug-resistant tuberculosis (XDR-TB; 55,000 cases worldwide), which is resistant 54 to any fluoroquinolone and at least one of three second line injectable drugs (SLID, i.e., 55 amikacin (AMK), kanamycin (KAN), or capreomycin (CAP)), is widely considered to be a 56 serious threat to global health (1). Treatment of MDR-TB is based on the association of 57 fluoroquinolones and SLID (2). As a consequence of inadequate use of second-line 58 treatments, XDR-TB, with an overall successful treatment outcome of only 50%, has 59 progressed (3). The lack of ability to perform Drug Susceptibility Testing (DST) is partly 60 responsible of the misuse of antituberculous drugs in several countries (1). 61 Rapid detection of drug resistance is essential to designing appropriate treatment regimens, 62 preventing treatment failure, and reducing the spread of drug-resistant isolates. Since 63 conventional phenotypic methods are cumbersome and take weeks to months to obtain drug 64 resistance profile, molecular assays for the detection of mutations that confer resistance have 65 been increasingly used, even in areas where DST capacities are very limited or not available, 66 and have the potential to shorten the time to detection of resistance to one working day (4-6).
67
The molecular tests for diagnosing resistance to antituberculous drugs are based on the 68 detection of mutations affecting the function and/or expression of chromosome-encoded 69 targets.
70
The SLID bind to the 16S rRNA in the 30S ribosomal subunit and inhibit protein synthesis 71 (7). Cross-resistance to second line injectable drugs (AMK, KAN and CAP) The SLID resistance-associated genes (rrs region 1400, eis promoter and tlyA) were amplified 122 and sequenced for the 206 MDR strains as previously reported (4), using the oligonucleotide 123 primers pairs previously described (4, 6 Table) .
145
The main clades corresponded to Beijing (44 S-SLID and 35 R-SLID), LAM (27 S-SLID and 146 11 R-SLID), Haarlem (11 S-SLID and 4 R-SLID) and non typeable strains generally linked to 147 the T strains family (35 S-SLID and 1 R-SLID). The remaining strains belonged to the S 148 (n=8), Ghana (n=6), Delhi-CAS (n=5), EAI (n=4), Ural (n=6), Cameroon (n=3), Uganda II 149 (n=2), NEW-1 (n=1), Bovis (n=1), Africanum (n=1), X (n=1) and TUR (n=1) families.
150
In total, 53 isolates were resistant to at least one of the three SLID. Among the 23 R-151 AMK/CAP/KAN isolates, 20 isolates showed a A1401G mutation (including one with an 152 additional C-14T mutation in the eis promoter), 1 isolate a C1402T mutation in rrs, and 2 153 isolates a C-14T mutation in the eis promoter (Table 1) (Table 1) . 168 Three strains were resistant to AMK and KAN, but susceptible to CAP ( detected no mutation on primary cultures, nor from the colonies growing on the CAP tubes. (Table 1) . 198 We included in our study 153 isolates susceptible to AMK/KAN/CAP. No mutation 199 was detected in these isolates, except for one isolate with a T1404C plus G1473A double 200 mutation in rrs, and for 7 isolates with eis promoter mutations (G-10A: n=3, C-12T: n=1, C-201 14T: n=1, G-37T: n=2) ( previously published by other groups, which reported mutations in rrs region 1400, mainly 220 A1401G, accounting for resistance to SLID for respectively: 56% to 100% for AMK, 51% to 221 96% for CAP and 44% to 84% for KAN (4, 5, 7, 8, 10-12, 14, 26, 27) . We observed in our 222 study that eis promoter mutations were present in 22/50 (44%) of the R-KAN strains on the 223 primary cultures. Among the detected mutations, G-10A, C-14T and G-37T were more 224 frequent (8/50 (16%), 6/50 (12%) and 7/50 (14%), respectively), while C-12T was rare (1/50 225 (2%)). It is noticeable that a significant number of S-KAN strains (7/156 (4.5%) also showed 226 mutations in the eis promoter (although these mutations are more common in R-KAN strains; 227 P = 0.0004) (see Table 1 ). Finally, no mutation in tlyA was observed in any of our isolates, so (4, 7, 8, 10, 11, 14, (26) (27) (28) (29) (30) (31) . while it is generally detected by using phenotypic DST (32 of discrepant S-KAN results observed in our study: 27% (3/11) for G-10A, 50% (1/2) for C- (Table 1) . Thus, AMK resistance in 296 these 2 isolates can be regarded as borderline and one cannot exclude that the 2 strains would a point that has to be considered when explaining the discrepancies between genotype and 301 phenotype, as previously suggested (9, 37).
302
The accuracy of the molecular tests in predicting susceptibility for AMK and CAP seems to 
316
One S-AMK/CAP/KAN strain (isolate no. 54) showed a double mutation T1404C plus 317 G1473A in rrs. If the rrs G1473A mutation has never been reported, rrs T1404C was 318 described by Walker et al in 53 strains including 51 susceptible to the 3 SLID, 1 R-KAN and 319 1 R-AMK (41). Therefore this mutation doesn't seem to be implicated in AMK, CAP or KAN 320 resistance, as confirmed by the low MICs found for our isolate (Table 1) . 321 Finally, for the unexpected susceptibility to CAP (MIC = 1 mg/liter) in 1 R-322 AMK/KAN isolate with a rrs A1401G mutation (mutation known to be associated with 323 AMK, KAN and also CAP resistance) (isolate n°24), this discrepancy also deserves to be 324 further investigated at the mechanistic level.
325
Our study has some limitations, in particular because we used a collection of strains 326 representative of clinical isolates received at the French Reference Center for Mycobacteria. 327 In this set of strains, among the MDR isolates, those with resistance to at least one SLID, and 328 particularly monoR-KAN, are associated with patients born in the Former Soviet Union (P = 329 0.0007 and P = 0.007, respectively). This association between monoR-KAN and Former
330
Soviet Union-born patients is not surprising since KAN is the preferred SLID in this country. 
